
Loading, please wait...

Loading, please wait...

The DEEP Phaser system employs a tandem vision transformer artificial neural network to process spectroscopic data. This sophisticated architecture allows the model to analyze global features across the entire spectral range simultaneously. Furthermore, the system achieves remarkable accuracy because developers trained it on extensive synthetic datasets mimicking real-world conditions. It efficiently handles both zeroth- and first-order corrections without requiring any manual tuning. Therefore, this advancement is particularly beneficial for high-throughput screening in modern drug development pipelines.
Beyond small molecules, DEEP Phaser proves effective for identifying biomarkers within complex biological mixtures. Moreover, the software is available as a public web server, making it accessible for researchers globally. In addition, the tool supports the structural verification of active pharmaceutical ingredients (APIs) with high reliability. Ultimately, these automated tools foster faster breakthroughs in personalized medicine and metabolic profiling by reducing data processing bottlenecks. Scientists can now focus more on interpreting results rather than performing routine technical adjustments.
DEEP Phaser is a deep learning-based algorithm designed for the automated NMR phase correction of 1D spectra. It utilizes a tandem vision transformer to ensure high accuracy without the need for manual expert intervention.
It automates a routine but tedious step in spectroscopy. Therefore, scientists can analyze more compounds in less time, significantly reducing the bottleneck in structural verification and purity assessment.
Yes, the tool has been demonstrated to work effectively on a variety of samples, ranging from simple small molecules to complex biomacromolecular mixtures.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or professional laboratory guidelines. Refer to the latest local and national guidelines for clinical practice.
References
1. Li DW et al. DEEP Phaser: A Deep Learning Tandem Vision Transformer for Fully Automated NMR Phase Correction. J Phys Chem Lett. 2026 May 04. doi: 10.1021/acs.jpclett.6c00770. PMID: 42081261.
2. Bruker Switzerland AG. Deep learning-based phase and baseline correction of 1D 1H NMR Spectra. Technical Note. 2025.
3. Zorin V et al. A robust, general automatic phase correction algorithm for high-resolution NMR data. Magnetic Resonance in Chemistry. 2024.

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


DEEP Phaser uses deep learning to automate NMR phase correction, improving accuracy and speed in drug discovery and complex molecular analysis....
5 months ago

Explore vital recurrent stroke predictors in lacunar stroke patients managed with intensive blood pressure lowering. This analysis examines trial findings from SPS3 to uncover residual vascular risks, metabolic factors, and targeted secondary prevention strategies for high-risk neurological patients.
Today

A comprehensive scoping review synthesises evidence linking prenatal maternal mental health to long-term offspring neurodevelopment, evaluating neuroendocrine, inflammatory, and epigenetic pathways while highlighting clinical screening and future research priorities.
Today

The Directorate General of Health Services directs Indian states to halt the hazardous reuse and reprocessing of single-use medical devices. Discover regulatory implications under the Drugs and Cosmetics Act, critical infection risks, legal liabilities, and operational changes required across clinical specialties.
Today

Mitochondria-targeted nanoparticles self-assembled from EGCG and L-glutamic acid effectively restore mitochondrial homeostasis, suppress synovial inflammation, and attenuate chondrocyte senescence in osteoarthritis, offering a promising disease-modifying nanotherapy.
Today

India is advancing preventive healthcare by integrating genomics, artificial intelligence, and quantum technologies. With the SANGAM programme sequencing one million Indian genomes, clinicians can unlock personalized therapies, detect cardiometabolic risks early, and curb the burden of diabetes and heart disease.
Today